ID: ALA2313377

Max Phase: Preclinical

Molecular Formula: C13H14ClN3OS

Molecular Weight: 295.80

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1nc2sc(C(=O)NC3CC3)c(N)c2c(C)c1Cl

Standard InChI:  InChI=1S/C13H14ClN3OS/c1-5-8-10(15)11(12(18)17-7-3-4-7)19-13(8)16-6(2)9(5)14/h7H,3-4,15H2,1-2H3,(H,17,18)

Standard InChI Key:  VIZLOCIWSKXQJN-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 295.80

Molecular Weight (Monoisotopic): 295.0546

AlogP: 3.04

#Rotatable Bonds: 2

Polar Surface Area: 68.01

Molecular Species: NEUTRAL

HBA: 4

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 0.07

CX LogP: 2.74

CX LogD: 2.74

Aromatic Rings: 2

Heavy Atoms: 19

QED Weighted: 0.89

Np Likeness Score: -1.98

References

1. Le U, Melancon BJ, Bridges TM, Vinson PN, Utley TJ, Lamsal A, Rodriguez AL, Venable D, Sheffler DJ, Jones CK, Blobaum AL, Wood MR, Daniels JS, Conn PJ, Niswender CM, Lindsley CW, Hopkins CR..  (2013)  Discovery of a selective M₄ positive allosteric modulator based on the 3-amino-thieno[2,3-b]pyridine-2-carboxamide scaffold: development of ML253, a potent and brain penetrant compound that is active in a preclinical model of schizophrenia.,  23  (1): [PMID:23177787] [10.1016/j.bmcl.2012.10.073]

2. Szabo M, Huynh T, Valant C, Lane JR, Sexton PM, Christopoulos A, Capuano B.  (2015)  A structureactivity relationship study of the positive allosteric modulator LY2033298 at the M4muscarinic acetylcholine receptor,  6  (11): [10.1039/C5MD00334B]

Source

Source(1):

• Scientific Literature